PTGX - Protagonist Therapeutics, Inc. Summary, Stock Quote and News | Benzinga

Market Overview

7.325 0.015 (0.21%)

Data as of Dec 14, 2019

Prev. Close 7.31
Price Open 7.3
Volume 332,631
Day's Range 7 - 7.6339
52 Wk Range 4.47 - 16.67
50 Day Moving Avg. 10.4
PE Ratio 0
Shares Outstanding 27.21M
Market Cap 199.29M

Trade PTGX stock with recommended broker Ally Invest. Commissions as low as $3.95.

Analyst Rating View All Ratings

72 Biggest Movers From Yesterday Lisa LevinThu, 05 Dec 2019 05:10:20 -0500
Mid-Afternoon Market Update: Dow Rises Over 200 Points; Barnes & Noble Education Shares Slide Lisa LevinWed, 04 Dec 2019 14:36:06 -0500
38 Stocks Moving In Wednesday's Mid-Day Session Lisa LevinWed, 04 Dec 2019 12:02:32 -0500
Mid-Day Market Update: Crude Oil Up 4%; Revance Therapeutics Shares Plunge Lisa LevinWed, 04 Dec 2019 12:02:19 -0500
Mid-Morning Market Update: Markets Open Higher; G-III Apparel Reports Mixed Q3 Results Lisa LevinWed, 04 Dec 2019 10:26:49 -0500
Protagonist Shares Resume Trade, Continue Higher, Now Up 69% For Session Benzinga NewsdeskWed, 04 Dec 2019 09:52:45 -0500
Protagonist Therapeutics Shares Halted On Circuit Breaker, Up 59.5% Benzinga NewsdeskWed, 04 Dec 2019 09:47:30 -0500
12 Healthcare Stocks Moving In Wednesday's Pre-Market Session Lisa LevinWed, 04 Dec 2019 07:34:55 -0500
The Daily Biotech Pulse: Roche's Tecentriq Snags FDA Nod For Lung Cancer, Rapt Out-Licenses Cancer Drug Shanthi RexalineWed, 04 Dec 2019 07:06:30 -0500
63 Biggest Movers From Yesterday Lisa LevinWed, 04 Dec 2019 05:15:28 -0500
{{ story.title }} {{ story.author }}{{ story.created }}

Show more Loading articles...

Protagonist Therapeutics Announces Preliminary Phase 2 Results with Hepcidin Mimetic PTG-300 in the Treatment of Transfusion Dependent Beta-Thalassemia PRNewswireDec 03, 2019
Protagonist Therapeutics to Present at Two Upcoming Healthcare Investor Conferences PRNewswireNov 13, 2019
Protagonist Therapeutics Reports Third Quarter 2019 Financial Results PRNewswireNov 06, 2019
Protagonist Therapeutics Announces First Patient Dosed in a Phase 2 Study of Oral IL-23 Receptor Antagonist PTG-200 (JNJ-67864238) in the Treatment of Crohn's Disease PRNewswireNov 06, 2019
Protagonist Therapeutics Secures Debt Facility for up to $50 Million PRNewswireOct 31, 2019
Protagonist Therapeutics Initiates Phase 2 Study of Novel Hepcidin Mimetic PTG-300 in the Treatment of Patients with Polycythemia Vera PRNewswireOct 30, 2019
Protagonist Therapeutics Announces Acceptance of Abstracts at the UEG Week 2019 Meeting and the ACG 2019 Annual Scientific Meeting PRNewswireOct 01, 2019
Protagonist Therapeutics to Present at the Cantor Global Healthcare Conference on Wednesday, October 2 PRNewswireSep 25, 2019
Protagonist Therapeutics Reports Granting of Inducement Awards PRNewswireSep 04, 2019
Protagonist Therapeutics to Present at the H.C. Wainwright & Co. 2019 Annual Healthcare Conference PRNewswireSep 03, 2019
{{ story.title }} {{ story.author }}{{ story.created }}

Show more Loading articles...

Omeros, Anavex Results Positive, Protagonist Suffers Setback: The Good, Bad, And Ugly Of Biopharma Seeking AlphaDec 05, 2019
SAGE, ESTC among premarket losers Seeking AlphaDec 05, 2019
CPST, CRC, RVNC and ORMP among notable midday movers Seeking AlphaDec 04, 2019
GPRO, CLVS among premarket gainers Seeking AlphaDec 04, 2019
Protagonist Therapeutics Inc (PTGX) President and CEO Dinesh V Patel Bought $–68,6…… of ... GuruFocusDec 03, 2019
CBL, CARA, VRAY and BOLD among midday movers Seeking AlphaDec 03, 2019
uniQure and ViewRay among healthcare gainers; Cara Therapeutics among losers Seeking AlphaDec 03, 2019
Protagonist down 26% on interim PTG-300 data in beta thalassemia Seeking AlphaDec 03, 2019
Protagonist -1.2%; may offer up to $75M in shares Seeking AlphaNov 27, 2019
Novo A Buys Milestone Pharmaceuticals Inc, SI-BONE Inc, Entasis Therapeutics Holdings Inc, ... GuruFocusNov 27, 2019
{{ story.title }} {{ story.author }}{{ story.created }}

Show more Loading articles...

Earnings View Earnings

Q3 2019	EST	Actual	Surprise
EPS:	Expected 2019-11-06
Rev:	Expected 2019-11-06

Q4 2019	EST	Actual	Surprise
EPS:	Expected 2020-03-10
Rev:	Expected 2020-03-10

Company Profile

Read More

Brokerage Center

Compare All Online Brokerages

Book A Demo

Learn How You Can Succeed In The Market With Benzinga Pro

Fastest Market News

Real-Time News Alerts

Customizable News Filters

Book A Demo